AMENDMENTS TO THE CLAIMS

**This listing of claims will replace all prior versions and listings of claims in the application:**

**LISTING OF CLAIMS:**

1. (original): A STAT 6 activation inhibitor which comprises a diaminopyrimidinecarboxamide derivative represented by a formula (I) or a salt thereof and a pharmaceutically acceptable carrier,



(I)

(symbols in the formula have the following meanings:

$A^1$: $CR^5$ or N,

$R^5$: -H, -lower alkyl, -O-lower alkyl or –halogen,

$A^2$: $CR^6$ or N,

$R^6$: -H or –halogen,

$R^3$: -$R^0$, –lower alkyl substituted with halogen, -halogen,

-$OR^0$, -S-lower alkyl, -CO-lower alkyl, -$CO_2$-lower alkyl,

-lower alkylene-OH, -hetero ring, -O-hetero ring, -N($R^0$)-hetero ring, -lower alkylene-hetero ring, -O-lower alkylene-hetero ring, -S-lower alkylene-hetero ring, -SO-lower alkylene-hetero ring, -$SO_2$-lower alkylene-hetero ring, -N($R^0$)-lower alkylene-hetero ring, -lower alkylene-CO-

hetero ring, -lower alkylene-$N(R^0)_2$, $-SO_2-N(R^0)$-lower alkyl or –lower alkylene-$N(R^0)-CO_2$-lower alkylene-phenyl,

$R^0$: the same or different from one another, and each is H or a lower alkyl,

n: 0 or 2,

$R^4$: (i) when n = 2, $-R^0$, –lower alkyl substituted with halogen, $-OR^0$, $-N(R^0)$-CHO, $-N(R^0)$-CO-lower alkyl or $-N(R^0)-SO_2$-lower alkyl,

(ii) when n = 0, -H, –lower alkyl substituted with halogen, -OH, -NH-CHO, $-CON(R^0)_2$, -lower alkylene substituted with halogen-OH, -lower alkylene-$NH_2$, -lower alkylene-$NHCONH_2$, -lower alkylene-$CO_2H$, -lower alkylene-$CO_2$-lower alkyl, -lower alkylene-CN, or –CH(lower alkylene-$OH)_2$, or a group represented by a formula -$X^a$-$R^{4a}$,

$X^a$: single bond, -O-, -CO-, -S-, $-SO_2-$, $-N(R^0)-$, $-N(R^0)CO-$, $-N(R^0)SO_2-$, -lower alkylene-O-, -lower alkylene-$N(R^0)-$, -lower alkylene-$N(R^0)CO-$, -lower alkylene-$N(R^0)SO_2-$, -lower alkylene-$N(R^0)CO_2-$, $-N(CO-R^0)-$, $-N(SO_2$-lower alkyl)-, $-CON(R^0)-$, -lower alkylene-O-CO-, -lower alkenylene-CO-, -lower alkenylene-$CON(R^0)-$, -lower alkenylene-$CO_2-$, $-O-(CH_2)_k$-cycloalkylene-$(CH_2)_m-$, $-N(R^0)-(CH_2)_k$-cycloalkylene-$(CH_2)_m-$, $-CO-(CH_2)_k$-cycloalkylene-$(CH_2)_m-$, $-CON(R^0)-(CH_2)_k$-cycloalkylene-$(CH_2)_m-$ or $-N(R^0)CO-(CH_2)_k$-cycloalkylene-$(CH_2)_m-$,

k and m, the same or different from each other, and each is 0, 1, 2, 3 or 4,

$R^{4a}$: lower alkyl, phenyl, hetero ring, cycloalkyl, lower alkylene-phenyl, lower alkylene-hetero ring, lower alkylene-OH, lower alkenyl, lower alkenylene-phenyl or lower alkenylene-hetero ring,

wherein the hetero rings in $R^3$ and $R^{4a}$ may be substituted with 1 to 5 of lower alkyl, halogen, $-OR^0$, -S-lower alkyl, -S(O)-lower alkyl, $-SO_2$-lower alkyl, lower alkylene-$OR^0$, $-N(R^0)_2$, $-CO_2R^0$, $-CON(R^0)_2$, -CN, -CHO,
$-SO_2N(R^0)_2$, $-N(R^0)$-$SO_2$-lower alkyl, $-N(R^0)$-CO-$N(R^0)_2$, $-N(R^0)$-$CO_2$-lower alkyl, $-N(R^0)$-$CO_2$-cycloalkyl, -NH-C(=NH)-NH-lower alkyl, -NH-C(=N-CN)-NH-lower alkyl, hetero ring (said hetero ring may be substituted with 1 to 5 substituents selected from lower alkyl, OH and lower alkylene-OH),
-lower alkylene-NH-C(=NN)-$NH_2$, -O-phenyl, -CO-phenyl,
$-N(R^0)$-CO-lower alkyl, $-N(R^0)$-CO-lower alkylene-$N(R^0)_2$,
-lower alkylene-$N(R^0)$-CO-lower alkylene-$N(R^0)_2$, -CO-$N(R^0)$-lower alkylene-$N(R^0)_2$, -CO-lower alkylene-$N(R^0)_2$, -CO-lower alkylene-$CO_2R^0$, -lower alkylene-$N(R^0)_2$, -lower alkylene-$CO_2R^0$, -lower alkylene-CO-$N(R^0)_2$, -lower alkylene-$N(R^0)$-CO-lower alkyl, -lower alkylene-$N(R^0)$-$CO_2$-lower alkyl, -lower alkylene-$N(R^0)$-$SO_2$-lower alkyl,-lower alkylene-hetero ring (said hetero ring may be substituted with 1 to 5 substituents selected from lower alkyl, OH and lower alkylene-OH), -lower alkylene-O-lower alkylene-phenyl,
=N-O-$R^0$ or oxo, and phenyl and cycloalkyl may be substituted with 1 to 5 of lower alkyl, OH, O-lower alkyl or $N(R^0)_2$, and
wherein the lower alkylene in $R^3$, $R^4$, $R^{4a}$ and $X^a$ may be substituted with 1 to 5 of $-OR^0$, $-CO_2R^0$, $-CON(R^0)_2$, $-N(R^0)_2$, $-N(R^0)COR^0$ or hetero ring, or
$R^3$ and $R^4$ may together form *-$N(R^7)$-$(CH_2)_2$-, *-$(CH_2)_2$-$N(R^7)$-, *-$CH_2$-$N(R^7)$-$CH_2$-, *-$N(R^7)$-$(CH_2)_3$-, *-$(CH_2)_3$-$N(R^7)$-, *-$CH_2$-$N(R^7)$-$(CH_2)_2$-, *-$(CH_2)_2$-$N(R^7)$-$CH_2$-, *-C(O)-$N(R^7)$-$(CH_2)_2$-, *-$(CH_2)_2$-$N(R^7)$-C(O)-, *-$N(R^7)$-CH=CH-, *-CH=CH-$N(R^7)$-,

*-N=CH-CH=CH-, *-CH=N-CH=CH-, *-CH=CH-N=CH-, *-CH=CH-CH=N-, *-N=CH-CH=N-, *-CH=N-N=CH-, *-N($R^7$)-N=CH-, *-CH=N-N($R^7$)-, *-O-$CH_2$-O-, *-O-$(CH_2)_2$-O-, *-O-$(CH_2)_3$-O-, *-O-$(CH_2)_2$-N($R^7$)-, *-$(CH_2)_2$-C(O)-, *-CH=CH-C(O)-O- or *-N=C($CF_3$)-NH-,

wherein * indicates bonding to the position shown by $R^3$,

$R^7$: -H, -lower alkyl or –CO-lower alkyl,

B: H, lower alkenyl, lower alkynyl, lower alkyl substituted with halogen, CN, S-lower alkyl, aryl which may have a substituent(s), cycloalkyl which may have a substituent(s) or hetero ring which may have a substituent(s),

Y: single bond; or lower alkylene which may be substituted with 1 to 5 groups selected from halogen, OH, O-lower alkyl, -$NH_2$, -NH-lower alkyl and –N(lower alkyl)$_2$, and

$R^1$ and $R^2$: the same or different from each other, and each represents H, lower alkyl or O-lower alkyl which may have a substituent(s)).

2. (original): The STAT 6 activation inhibitor described in claim 1, which is a Th2 cell differentiation inhibitor.

3. (original): A diaminopyrimidinecarboxamide derivative represented by a formula (Ia) or a salt thereof,




(Ia)

(symbols in the formula have the following meanings:

$A^1$: $CR^5$ or N,

$R^5$: -H, -lower alkyl, -O-lower alkyl or –halogen,

$R^3$: $-R^0$, –lower alkyl substituted with halogen, -halogen,

$-OR^0$, -S-lower alkyl, -CO-lower alkyl, $-CO_2$-lower alkyl,

-lower alkylene-OH, -saturated hetero ring, $-X^b$-heteroaryl, $-X^b$-saturated hetero ring, $-X^b$-heteroaryl, -lower alkylene-$N(R^0)_2$, $-SO_2-N(R^0)$-lower alkyl or –lower alkylene-$N(R^0)-CO_2$-lower alkylene-phenyl,

$X^b$: -lower alkylene-, -O-lower alkylene-, -S-lower alkylene-, -SO-lower alkylene-, $-SO_2$-lower alkylene-,

$-N(R^0)$-lower alkylene- or -lower alkylene-CO-,

$R^0$: the same or different from one another, and each represents H or a lower alkyl,

$R^4$: $-X^a$-saturated hetero ring, -lower alkylene-saturated hetero ring or –lower alkenylene-saturated hetero ring,

$X^a$: single bond, -O-, -CO-, -S-, $-SO_2$-, $-N(R^0)$-,

$-N(R^0)CO$-, $-N(R^0)SO_2$-, -lower alkylene-O-, -lower alkylene-$N(R^0)$-, -lower alkylene-$N(R^0)CO$- or -lower alkylene-$N(R^0)SO_2$-, -lower alkylene-$N(R^0)CO_2$-, $-N(CO-R^0)$-, $-N(SO_2$-lower alkyl)-, $-CON(R^0)$-, -lower alkylene-O-CO-, -lower alkenylene-CO-, -lower alkenylene-$CON(R^0)$-, -lower alkenylene-$CO_2$-, $-O-(CH_2)_k$-cycloalkylene-$(CH_2)_m$-, $-N(R^0)-(CH_2)_k$-cycloalkylene-$(CH_2)_m$-, $-CO-(CH_2)_k$-cycloalkylene-$(CH_2)_m$-, $-CON(R^0)-(CH_2)_k$-cycloalkylene-$(CH_2)_m$- or $-N(R^0)CO-(CH_2)_k$-cycloalkylene-$(CH_2)_m$-,

k and m: the same or different from each other, and each is 0, 1, 2, 3 or 4,

wherein the saturated hetero rings in $R^3$ and $R^{4a}$ may be substituted with 1 to 5 of lower alkyl, halogen, $-OR^0$,

-S-lower alkyl, -S(O)-lower alkyl, -$SO_2$-lower alkyl, lower alkylene-$OR^0$, -$N(R^0)_2$, -$CO_2R^0$, -$CON(R^0)_2$, -CN, -CHO,

-$SO_2N(R^0)_2$, -$N(R^0)$-$SO_2$-lower alkyl, -$N(R^0)$-CO-$N(R^0)_2$, -$N(R^0)$-$CO_2$-lower alkyl, -$N(R^0)$-$CO_2$-cycloalkyl, -NH-C(=NH)-NH-lower alkyl, -NH-C(=N-CN)-NH-lower alkyl, saturated hetero ring (said hetero ring may be substituted with 1 to 5 substituents selected from lower alkyl, OH and lower alkylene-OH), heteroaryl, -lower alkylene-NH-C(=NN)-$NH_2$,

-O-phenyl, -CO-phenyl, -$N(R^0)$-CO-lower alkyl, -$N(R^0)$-CO-lower alkylene-$N(R^0)_2$, -lower alkylene-$N(R^0)$-CO-lower alkylene-$N(R^0)_2$, -CO-$N(R^0)$-lower alkylene-$N(R^0)_2$, -CO-lower alkylene-$N(R^0)_2$, -CO-lower alkylene-$CO_2R^0$,

-lower alkylene-$N(R^0)_2$, -lower alkylene-$CO_2R^0$, -lower alkylene-CO-$N(R^0)_2$, -lower alkylene-$N(R^0)$-CO-lower alkyl,

-lower alkylene-$N(R^0)$-$CO_2$-lower alkyl, -lower alkylene-$N(R^0)$-$SO_2$-lower alkyl, -lower alkylene-hetero ring (said hetero ring may be substituted with 1 to 5 substituents selected from lower alkyl, OH and lower alkylene-OH),

-lower alkylene-O-lower alkylene-phenyl, =N-O-$R^0$ or oxo, and phenyl and cycloalkyl may be substituted with 1 to 5 of lower alkyl, OH, O-lower alkyl or $N(R^0)_2$, and

wherein the lower alkylene in $R^3$, $R^4$ and $X^a$ may be substituted with 1 to 5 of -$OR^0$, -$CO_2R^0$, -$CON(R^0)_2$, -$N(R^0)_2$, -$N(R^0)COR^0$ or hetero ring, or

$R^3$ and $R^4$ may together form *-$N(R^7)$-$(CH_2)_2$-, *-$(CH_2)_2$-$N(R^7)$-, *-$CH_2$-$N(R^7)$-$CH_2$-, *-$N(R^7)$-$(CH_2)_3$-,

*-$(CH_2)_3$-$N(R^7)$-, *-$CH_2$-$N(R^7)$-$(CH_2)_2$-, *-$(CH_2)_2$-$N(R^7)$-$CH_2$-,

*-C(O)-$N(R^7)$-$(CH_2)_2$-, *-$(CH_2)_2$-$N(R^7)$-C(O)-, *-$N(R^7)$-CH=CH-, *-CH=CH-$N(R^7)$-, *-N=CH-CH=CH-, *-CH=N-CH=CH-,

*-CH=CH-N=CH-, *-CH=CH-CH=N-, *-N=CH-CH=N-, *-CH=N-N=CH-, *-N($R^7$)-N=CH-, *-CH=N-N($R^7$)-, *-O-$CH_2$-O-, *-O-$(CH_2)_2$-O-,

*-O-$(CH_2)_3$-O-, *-O-$(CH_2)_2$-N($R^7$)-, *-$(CH_2)_2$-C(O)-, *-CH=CH-C(O)-O- or *-N=C($CF_3$)-NH-,

wherein * indicates bonding to the position shown by $R^3$,

$R^7$: -H, -lower alkyl or –CO-lower alkyl,

B: aryl which may have a substituent(s) or heteroaryl which may have a substituent(s), and

$R^1$ and $R^2$: the same or different from each other, and each represents H, lower alkyl or O-lower alkyl which may have a substituent(s)).

4. (original): A diaminopyrimidinecarboxamide derivative represented by a formula (Ib) or a salt thereof,




(Ib)

(symbols in the formula have the following meanings:

$A^1$: $CR^5$ or N,

$R^5$: -H, -lower alkyl, -O-lower alkyl or –halogen,

$R^3$: -saturated hetero ring or –$X^b$-saturated hetero ring,

$X^b$: -lower alkylene-, -O-, –N($R^0$)-, -O-lower alkylene-, -S-lower alkylene-, -SO-lower alkylene-, -$SO_2$-lower alkylene-, –N($R^0$)-lower alkylene- or –lower alkylene-CO-,

$R^0$: the same or different from one another, and each represents H or a lower alkyl,

$R^4$: -H, –lower alkyl substituted with halogen, -OH, -NH-CHO, -CON($R^0$)$_2$, –lower alkylene substituted with

halogen-OH, -lower alkylene-$NH_2$, -lower alkylene-$NHCONH_2$,

-lower alkylene-$CO_2H$, -lower alkylene-$CO_2$-lower alkyl,

-lower alkylene-CN, –CH(lower alkylene-OH)$_2$ or –$X^a$-$R^{4a}$,

$X^a$: single bond, -O-, -CO-, -S-, -$SO_2$-, -N($R^0$)-,

-N($R^0$)CO-, -N($R^0$)$SO_2$-, -lower alkylene-O-, -lower alkylene-N($R^0$)-, -lower alkylene-N($R^0$)CO- or -lower alkylene-N($R^0$)$SO_2$-, -lower alkylene-N($R^0$)$CO_2$-, -N(CO-$R^0$)-, -N($SO_2$-lower alkyl)-, -CON($R^0$)-, -lower alkylene-O-CO-, -lower alkenylene-CO-, -lower alkenylene-CON($R^0$)-, -lower alkenylene-$CO_2$-, -O-$(CH_2)_k$-cycloalkylene-$(CH_2)_m$-, -N($R^0$)-$(CH_2)_k$-cycloalkylene-$(CH_2)_m$-, -CO-$(CH_2)_k$-cycloalkylene-$(CH_2)_m$-, -CON($R^0$)-$(CH_2)_k$-cycloalkylene-$(CH_2)_m$- or -N($R^0$)CO-$(CH_2)_k$-cycloalkylene-$(CH_2)_m$-,

k and m: the same or different from each other, and each is 0, 1, 2, 3 or 4,

$R^{4a}$: lower alkyl, phenyl, heteroaryl, cycloalkyl, lower alkylene-phenyl, lower alkylene-heteroaryl, lower alkylene-OH, lower alkenyl, lower alkenylene-phenyl or lower alkenylene-heteroaryl,

wherein the saturated hetero ring and heteroaryl in $R^3$ and $R^{4a}$ may be substituted with 1 to 5 of lower alkyl, halogen, -$OR^0$, -S-lower alkyl, -S(O)-lower alkyl, -$SO_2$-lower alkyl, lower alkylene-$OR^0$, -N($R^0$)$_2$, -$CO_2R^0$, -CON($R^0$)$_2$, -CN, -CHO, -$SO_2$N($R^0$)$_2$, -N($R^0$)-$SO_2$-lower alkyl, -N($R^0$)-CO-N($R^0$)$_2$, -N($R^0$)-$CO_2$-lower alkyl, -N($R^0$)-$CO_2$-cycloalkyl, -NH-C(=NH)-NH-lower alkyl, -NH-C(=N-CN)-NH-lower alkyl, hetero ring (said hetero ring may be substituted with 1 to 5 substituents selected from lower alkyl, OH and lower alkylene-OH), -lower alkylene-NH-C(=NN)-$NH_2$, -O-phenyl,

-CO-phenyl, -N($R^0$)-CO-lower alkyl, -N($R^0$)-CO-lower alkylene-N($R^0$)$_2$, -lower alkylene-N($R^0$)-CO-lower alkylene-N($R^0$)$_2$, -CO-N($R^0$)-lower alkylene-N($R^0$)$_2$, -CO-lower alkylene-N($R^0$)$_2$, -CO-lower alkylene-$CO_2R^0$, -lower alkylene-N($R^0$)$_2$,

-lower alkylene-$CO_2R^0$, -lower alkylene-CO-N($R^0$)$_2$, -lower alkylene-N($R^0$)-CO-lower alkyl, -lower alkylene-N($R^0$)-$CO_2$-lower alkyl, -lower alkylene-N($R^0$)-$SO_2$-lower alkyl, -lower alkylene-hetero ring (said hetero ring may be substituted with 1 to 5 substituents selected from lower alkyl, OH and lower alkylene-OH), -lower alkylene-O-lower alkylene-phenyl, =N-O-$R^0$ or oxo, and phenyl and cycloalkyl may be substituted with 1 to 5 of lower alkyl, OH, O-lower alkyl or N($R^0$)$_2$, or

the lower alkylene in $R^3$, $R^4$, $R^{4a}$ and $X^a$ may be substituted with 1 to 5 of -$OR^0$, -$CO_2R^0$, -CON($R^0$)$_2$, -N($R^0$)$_2$, -N($R^0$)COR$^0$ or hetero ring, or

$R^3$ and $R^4$ may together form *-N($R^7$)-$(CH_2)_2$-, *-$(CH_2)_2$-N($R^7$)-, *-$CH_2$-N($R^7$)-$CH_2$-, *-N($R^7$)-$(CH_2)_3$-,

*-$(CH_2)_3$-N($R^7$)-, *-$CH_2$-N($R^7$)-$(CH_2)_2$-, *-$(CH_2)_2$-N($R^7$)-$CH_2$-,

*-C(O)-N($R^7$)-$(CH_2)_2$-, *-$(CH_2)_2$-N($R^7$)-C(O)-, *-N($R^7$)-CH=CH-, *-CH=CH-N($R^7$)-, *-N=CH-CH=CH-, *-CH=N-CH=CH-, *-CH=CH-N=CH-, *-CH=CH-CH=N-, *-N=CH-CH=N-, *-CH=N-N=CH-, *-N($R^7$)-N=CH-, *-CH=N-N($R^7$)-, *-O-$CH_2$-O-, *-O-$(CH_2)_2$-O-, *-O-$(CH_2)_3$-O-, *-O-$(CH_2)_2$-N($R^7$)-, *-$(CH_2)_2$-C(O)-, *-CH=CH-C(O)-O- or *-N=C($CF_3$)-NH-, wherein * indicates bonding to the position shown by $R^3$,

$R^7$: -H, -lower alkyl or –CO-lower alkyl,

B: aryl which may have a substituent(s) or heteroaryl which may have a substituent(s), and

$R^1$ and $R^2$: the same or different from each other, and each represents H, lower alkyl or O-lower alkyl which may have a substituent(s)).

5. (original): A diaminopyrimidinecarboxamide derivative represented by a formula (Ic) or a salt thereof,




(Ic)

(symbols in the formula have the following meanings:

$R^5$: -H or –halogen,

B: phenyl which may have 1 to 3 substituents selected from lower alkyl and halogen,

Y: single bond or $-CH_2-$, and

$R^1$ and $R^2$: the same or different from each other, and each represents H or lower alkyl which may have a substituent(s)).

6. (currently amended): A diaminopyrimidinecarboxamide selected from the group consisting of 4-benzylamino-2-[(4-morpholin-4-ylphenyl)amino]pyrimidine-5-carboxamide, 2-[(4-morpholin-4-ylphenyl)amino]-4-[(2,3,6-trifluorobenzyl)amino]pyrimidine-5-carboxamide, 4-[(2,6-difluorobenzyl)amino]-2-[(4-morpholin-4-ylphenyl)amino]pyrimidine-5-carboxamide, 4-[(2,6~~5~~-difluorobenzyl)amino]-2-[(4-morpholin-4-ylphenyl)amino]pyrimidine-5-carboxamide, 4-[(2-methoxybenzyl)amino]-2-[(4-morpholin-4-ylphenyl)amino]pyrimidine-5-carboxamide, 4-[(2-fluoro-6-methoxybenzyl)amino]-2-[(4-morpholin-4-ylphenyl)amino]pyrimidine-5-carboxamide, 2-({4-[(1-methylpiperidin-3-yl)oxy]phenyl}amino)-4-[(2,3,6-trifluorobenzyl)amino]pyrimidine-5-carboxamide, 2-{[4-(1-azabicyclo[2.2.2]oct-3-

yloxy)phenyl]amino}-4-[(2,3,6-trifluorobenzyl)amino]pyrimidine-5-carboxamide, 2-[(4-methyl-3,4-dihydro-2H-1,4-benzoxazin-7-yl)amino]-4-[(2,3,6-trifluorobenzyl)amino]pyrimidine-5-carboxamide, 2-({4-[4-(2-amino-2-oxoethyl)piperazin-1-yl]phenyl}amino)-4-[(2,3,6-trifluorobenzyl)amino]pyrimidine-5-carboxamide, 2-{[4-(2-morpholin-4-ylethoxy)phenyl]amino}-4-[(2,3,6-trifluorobenzyl)amino]pyrimidine-5-carboxamide, 2-{[4-(β-D-glucopyranosyloxy)phenyl]amino}-4-[(2,3,6-trifluorobenzyl)amino]pyrimidine-5-carboxamide, 4-benzylamino-2-{[2-(3-chloro-4-hydroxyphenyl)ethyl]amino}pyrimidine-5-carboxamide, 4-benzylamino-2-{[2-(3,5-dichloro-4-hydroxyphenyl)ethyl]amino}pyrimidine-5-carboxamide, 2-[(4-morpholin-4-ylphenyl)amino]-4-[(2-thienylmethyl)amino]pyrimidine-5-carboxamide, 4-{[(3-chloro-2-thienyl)methyl]amino}-2-[(4-morpholin-4-ylphenyl)amino]pyrimidine-5-carboxamide and 2-{[3-(2-morpholin-4-ylethyl)phenyl]amino}-4-[(2,3,6-trifluorobenzyl)amino]pyrimidine-5-carboxamide or salts thereof.

7. (original): A pharmaceutical composition which comprises the diaminopyrimidinecarboxamide derivative or a salt thereof described in claims 3 to 6 and a pharmaceutically acceptable carrier.

8. (original): The composition described in claim 7, which is a preventive or therapeutic agent for respiratory diseases.

9. (original): The composition described in claim 8, which is a preventive or therapeutic agent for asthma.

10. (original): The composition described in claim 8, which is a preventive or therapeutic agent for a chronic obstructive pulmonary disease.

11. (original): Use of a diaminopyrimidinecarboxamide derivative represented by the general formula (I) described in claim 1, or a salt thereof, for the manufacture of an STAT 6 activation inhibitor.

12. (original): Use of a diaminopyrimidinecarboxamide derivative represented by the general formula (I) described in claim 1, or a salt thereof, for the manufacture of a Th2 cell differentiation inhibitor.

13. (original): A method for inhibitory activity for STAT 6 activation, which comprises administering an effective amount of a diaminopyrimidinecarboxamide derivative represented by the general formula (I) described in claim 1, or a salt thereof, to a mammal.

14. (original): A method for inhibitory activity for Th2 cell differentiation, which comprises administering an effective amount of a diaminopyrimidinecarboxamide derivative represented by the general formula (I) described in claim 1, or a salt thereof, to a mammal.